SCHEMBL5494945

SCHEMBL5494945

CC(=O)Oc1cnc(C)nc1O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.37
TSHR P16473 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
LMNA P02545 1/20 0.34
ALDH1A1 P00352 4/20 0.34
KDM4E B2RXH2 4/20 0.34
TDP1 Q9NUW8 3/20 0.34
HPGD P15428 2/20 0.34
BLM P54132 2/20 0.34
TNFSF11 O14788 1/20 0.34
ESR1 P03372 1/20 0.34
ITGB3 P05106 1/20 0.34
ITGA2B P08514 1/20 0.34
HMGB1 P09429 1/20 0.34
GGT1 P19440 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
NAPRT Q6XQN6 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ACHE P22303 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16742632 0.83 HTT (0.38) HTTTSHRSMN1; SMN2LMNAALDH1A1
SCHEMBL4046039 0.80 LMNA (0.42) HTTTSHRSMN1; SMN2LMNAALDH1A1
SCHEMBL5501359 0.80 KDM4E (0.41) HTTTSHRSMN1; SMN2LMNAALDH1A1
SCHEMBL907644 0.79 TNFSF11 (0.40) HTTTSHRSMN1; SMN2ALDH1A1KDM4E
SCHEMBL10361048 0.77 ALDH1A1 (0.32) HTTTSHRALDH1A1KDM4ETDP1
SCHEMBL9045721 0.76 P2RX3 (0.37) TSHRSMN1; SMN2LMNAALDH1A1KDM4E
SCHEMBL5500327 0.75 PDE10A (0.36) ALDH1A1KDM4ETDP1BLMPTGS2
SCHEMBL23937860 0.72 PIK3C3 (0.35) LMNAMAPTKMT2APOLBMEN1
SCHEMBL17706548 0.71 POLB (0.51) SMN1; SMN2LMNAALDH1A1KDM4ETDP1
SCHEMBL24786404 0.70 LMNA (0.50) TSHRSMN1; SMN2LMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1005470-B1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2007-08-01 EP disclosed
US-6294532-B1 TREATMENT OF A NUMBER OF DISEASE STATES INCLUDING CANCER AND RHEUMATOID ARTHRITIS. ZENECA LIMITED (GB) 2001-09-25 US disclosed
EP-1005470-A1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ZENECA LIMITED (GB) 2000-06-07 EP disclosed
WO-1999010349-A1 OXINDOLYLQUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ZENECA LIMITED (GB) 1999-03-04 WO disclosed
EP-0222210-B1 PROCESS FOR PREPARING PHOSPHORIC-ACID DERIVATIVES AND INTERMEDIATES BAYER AG (DE) 1990-03-28 EP disclosed
US-4769458-A Process for the preparation of phosphoric acid derivatives and intermediate products BAYER AKTIENGESELLSCHAFT (DE) 1988-09-06 US disclosed
EP-0222210-A2 Process for preparing phosphoric-acid derivatives and intermediates BAYER AG (DE) 1987-05-20 EP disclosed